AKT1 and non-small cell lung carcinoma: The results of in vivo study further confirmed that Shikonin suppressed afatinib-resistant NSCLC xenograft tumor growth by decreasing p-Akt, Bcl-2 expression and increasing cleaved caspase-3, Bax expression.